Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Probiotic strain for reducing blood uric acid, composition and application of the probiotic strain

A technology of composition and blood uric acid, applied in the direction of application, microorganism, drug combination, etc., can solve the problems of indigestion and decomposition of purine precursors, probiotic strains have no effect, etc.

Active Publication Date: 2021-08-06
宁波倍益嘉生物科技有限公司
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is a serious flaw in this test method. Living microorganisms need nutrients to maintain their own survival at all times. In an environment lacking nutrients, microorganisms will be forced to digest and absorb some nutrients that are not used under normal conditions in order to survive. However, once the nutrients are abundant, the microorganisms will not preferentially utilize these nutrients. Therefore, the probiotics screened through this reaction system containing only purine precursor substrates, after entering the human body, will Under the condition of abundant nutrients in the intestine, probiotics may not digest and decompose purine precursors (nucleosides, nucleotides, deoxynucleosides, deoxynucleotides, etc.) substrates, so the screened probiotic strains are used in practical applications may not be effective in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Probiotic strain for reducing blood uric acid, composition and application of the probiotic strain
  • Probiotic strain for reducing blood uric acid, composition and application of the probiotic strain
  • Probiotic strain for reducing blood uric acid, composition and application of the probiotic strain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1: Screening of probiotics

[0037] The probiotic strains to be tested (including Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus gravidarum) screened and preserved in this laboratory Bacillus, Lactobacillus fermentum and other 10 species belong to more than 130 strains of lactic acid bacteria probiotic strains, Bifidobacterium animalis, Bifidobacterium longum, Bifidobacterium infantis, Pediococcus lactis), were activated, inoculated into MRS medium for cultivation, at 37 Cultivate facultative anaerobic (standstill) or strict anaerobic (oxygen concentration 600 =2.7(1OD is about 2.0-3.0*10 8 CFU / ml), respectively added to the phosphate test buffer system (20mM, pH6.86) containing 0.7mg / mL adenylic acid, guanylic acid, inosine, adenosine, guanosine and inosine, the cells The final concentration is OD 600 = 0.6, incubated at ...

Embodiment 2

[0055] Example 2: Re-screening of the ability of probiotics to degrade purine precursors under nutrient conditions

[0056] The human intestinal tract is a nutrient-rich environment. Probiotics degrade purine nucleosides and nucleotides under non-nutritional conditions that only contain nucleosides and nucleotide substrates, and cannot guarantee degradation under rich nutrient conditions in the intestine Therefore, it is very important to select a screening condition that contains nutrients and does not affect the detection. After screening and optimization, the inventor has screened out a nutrient-containing test system that can ensure the growth of the bacteria and does not affect the detection. It consists of: 20mM phosphate; 0.2% glucose, 0.25% yeast powder and 0.2% ammonium sulfate , pH6.86. The dominant probiotic strains screened in Example 1 were re-screened in the above-mentioned test buffer containing nutrients. Adjust candidate strains to OD 600 It is 2.7, join in...

Embodiment 3

[0066] Example 3. Purine-reducing screening of candidate Lactobacillus depurines under different pH conditions

[0067] The human intestinal tract ranges from pH 5.5 in the duodenum to pH 7.5 in the large intestine. In order to screen probiotics that can degrade purine precursors throughout the intestinal tract, we selected the candidate Luo Lactobacillus eiferii was tested for purine reduction under the simulated human intestinal environment pH (5.0-7.5). Guanosine and adenosine were selected as substrates for testing. Since the main activity of KLR-3 and KLR-10 is to degrade nucleotides, their test substrates are guanylic acid and adenosic acid. The test results (Table 8) show that Lactobacillus reuteri KLR-1, KLR- 13 The activities of norguanosine and adenosine in different pH environments are relatively stable, and the activities of norguanosine and adenosine in Lactobacillus reuteri KLR-3 are relatively stable in different pH environments, while KLR-10 is relatively stab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
hardnessaaaaaaaaaa
Login to View More

Abstract

The invention discloses a probiotic strain for reducing blood uric acid, a composition and application of the probiotic strain. The purine reduction capacity of probiotics is screened under the condition of rich culture media for the first time, a culture environment relatively simulating human intestinal tracts is obtained, lactobacillus reuteri KLR-1 is obtained, the preservation number of the lactobacillus reuteri KLR-1 is CGMCC No.18699, a lactobacillus reuteri strain is lactobacillus reuteri KLR-3, the preservation number of the lactobacillus reuteri KLR-3 is CGMCC No.18700, a lactobacillus reuteri strain is lactobacillus reuteri KLR-13, the preservation number of the lactobacillus reuteri KLR-3 is CGMCC No.19329, meanwhile, the probiotic composition provided by the invention contains at least one of the above-mentioned probiotics. In an animal model, the probiotics or the composition has an obvious uric acid reducing effect, the probiotics are mutually coordinated, and the blood uric acid reducing effect of the composition is obviously superior to that of single probiotics; as a new means for reducing blood uric acid and treating gout, the probiotic strain and the composition have a wide application prospect.

Description

technical field [0001] The invention belongs to the field of prevention and treatment of hyperuricemia and gout, and in particular relates to a probiotic strain for reducing blood uric acid, a probiotic composition and applications thereof. Background technique [0002] Hyperuricemia is a chronic metabolic disease, clinically manifested by blood uric acid levels higher than the normal range (male > 420 μmol / L, female > 360 μmol / L). In addition to gout caused by uric acid crystals, patients with hyperuricemia may also develop kidney disease, urinary tract stones, arteriosclerosis, cardiovascular disorders, and cerebrovascular disorders. According to reports, the number of patients with hyperuricemia in my country has reached 170 million, of which more than 80 million patients with gout, and is rapidly increasing at an annual growth rate of 9.7%. In China, gout has become the second largest metabolic disease after diabetes. [0003] Under normal physiological condition...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20A61K35/747A61P19/06A23L33/135C12R1/225
CPCA61K35/747A61P19/06A23L33/135A23V2002/00A23V2200/326A23V2200/30A23V2400/173Y02A50/30
Inventor 刘海峰李春艳刘艳红陈雅珊
Owner 宁波倍益嘉生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com